World News
IN SHORT
Saturday, November 17, 2018

Channels
frontpage
world
entertainment
odd news
politics
science
technology
health
sports
business

Latest
Overview
world
entertainment
odd news
politics
science
technology
health
sports
business
AD
Roche scores win in slowing aggressive type of breast cancer
JAY GORY, MANAGING EDITOR, science
Trial data released on Saturday shed light on the treatment of triple-negative tumors, which affect 15 percent of breast cancer patients, typically affecting younger-than-average women. Tecentriq's benefit was shown to be greatest among the roughly 40 percent of trial participants who had high levels of a protein known as PD-L1, which helps tumors avoid immune system detection. Peter Schmid, clinical director of St. Bartholomew's Breast Cancer Centre in London and the study's lead author, said the results "will change the way triple-negative breast cancer is treated". read more


(Possibly) Related news

More in science